HCW Biologics Inc.
13F holders, Q3 2024 (September 30)16holders −3
0new positions
3sold out
$0.54avg. 13F price*
At the end of Q3 2024, 16 institutions reported holding HCW Biologics Inc. in their 13F filings, down 3 from Q2 2024. 0 opened new positions and 3 sold out. The largest holders were Avantax Planning Partners, Inc. ($151K), Geode Capital Management, LLC ($99K) and HighTower Advisors, LLC ($98K).
- Company
- HCW Biologics Inc.
- CUSIP
- 40423R105
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 3 | $25K |
All 13F filers, Q2 2024 → Q3 2024: 13,603 shares bought and 68,950 shares sold, net −55,347 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Avantax Planning Partners, Inc. | 0.01% | No change | 279,541 | $151K |
| Geode Capital Management, LLC | 0.00% | Add +7.6% | 183,259 | $99K |
| HighTower Advisors, LLC | 0.00% | No change | 180,810 | $98K |
| Cresset Asset Management, LLC | 0.00% | No change | 131,990 | $71K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 84,700 | $46K |
| Pullen Investment Management, LLC | 0.03% | Reduce -11.8% | 75,116 | $41K |
| HRT Financial LP | 0.00% | Reduce -30.3% | 46,497 | $25K |
| BlackRock, Inc. | 0.00% | — | 44,348 | $24K |
| Vanguard Group Inc. | 0.00% | No change | 37,677 | $20K |
| AE Wealth Management LLC | 0.00% | No change | 30,000 | $16K |
| Two Sigma Investments, LP | 0.00% | Reduce -0.2% | 22,443 | $12K |
| State Street Corp. | 0.00% | No change | 21,446 | $12K |
| Northern Trust Corp. | 0.00% | No change | 10,205 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -5.3% | 5,881 | $3K |
| UBS Group AG | 0.00% | Add +12.7% | 4,831 | $3K |
| Bank of America Corp. | 0.00% | Add +117.3% | 339 | $183 |
"% of holder's portfolio" is HCW BIOLOGICS INC's weight in each manager's 13F, not the share of HCW Biologics Inc. the manager owns.